Point mutation inactivation and reduced SHIP1 gene activity have been observed in patients with AML, and the miR-155-mediated suppression of SHIP1 expression is involved in the pathogenesis of AML. The gene discussed is INPP5D; the disease is acute myeloid leukemia.